Ronald Sugar - Amgen Insider

Amgen Inc -- USA Stock  

USD 186.11  0.18  0.10%

Independent Director

Dr. Ronald D. Sugar, Ph.D., is an Independent Director of Amgen Inc. Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporationrationration, a global aerospace and defense company, having held these posts from 2003 through 2009. Dr. Sugar was a director of Chevron Corporationrationration, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee and of Air Lease Corporationrationration, an aircraft leasing company, since 2010, chairing the Compensation Committee and serving on the Governance Committee. Since 2010, he was a senior advisor to Ares Management LLC, a privatelyheld asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings Limited, a privatelyheld investment company based in Singapore
Age: 67  Director Since 2010      
805 447-1010  www.amgen.com
Sugar is a member of the National Academy of Engineering, trustee of the University of Southern California, member of the UCLA Anderson School of Management Board of Advisors, director of the Los Angeles Philharmonic Association and national trustee of the Boys and Girls Clubs of America.

Ronald Sugar Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Ari BousbibQuintiles IMS Holdings Inc
2016
Fred WeissAllergan plc
2013
William OsbornAbbott Laboratories
2013
James FasanoQuintiles IMS Holdings Inc
2016
Nesli BasgozAllergan plc
2014
William YoungVertex Pharmaceuticals Incorpor
2014
John DanhaklQuintiles IMS Holdings Inc
2016
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Joseph BoccuziAllergan plc
2017
Richard RelyeaQuintiles IMS Holdings Inc
2013
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Todd SisitskyEndo International plc
2016
Roxanne AustinAbbott Laboratories
2000
Daniel StarksAbbott Laboratories
2017
David GreenwayVertex Pharmaceuticals Incorpor
2017
Patrick OSullivanAllergan plc
2013
Samuel ScottAbbott Laboratories
2007
Ronald TaylorAllergan plc
2013
Alice SchwartzBio Rad Laboratories Inc
1967
Alan GarberVertex Pharmaceuticals Incorpor
2017
William SpenglerEndo International plc
2008

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Backtesting Now
   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
Hide  View All  Next  Launch Portfolio Backtesting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators